Drug, across the briefings
Orantinib across 13 cancers
Orantinib appears in 13 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Bladder cancer | phase 3 on FGFR3 | — | — | |
| Cholangiocarcinoma | phase 3 on FGFR2 | — | — | |
| Gallbladder cancer | phase 3 on FGFR2 | — | — | |
| Gastric cancer | phase 3 on FGFR2, KDR | 1 | 0 | |
| Gastrointestinal stromal tumour | phase 3 on PDGFRA | — | — | |
| Glioblastoma | phase 3 on PDGFRA | — | — | |
| Hepatocellular carcinoma | phase 3 on FGFR4, KDR | 2 | 0 | |
| Kidney cancer | phase 3 on KDR | 1 | 0 | |
| Lower-grade glioma | phase 3 on PDGFRA | — | — | |
| Osteosarcoma | phase 3 on KDR | — | — | |
| Rhabdomyosarcoma | phase 3 on FGFR4 | — | — | |
| Small intestine cancer | phase 3 on PDGFRA | — | — | |
| Soft tissue sarcoma | phase 3 on PDGFRA, PDGFRB | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.